|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1992-9-10
|
|
pubmed:abstractText |
The action of IFN-alpha has been studied in patients with carcinoid tumours. More than 300 patients have been treated with IFN-alpha for long periods of time (median 2.5 years). IFN-alpha exerts many pleiotrophic effects in carcinoid tumours. Antiproliferative effects are manifest mainly by a cell cycle block in GO-G1 phase and prolongation of the S-phase. Hormone synthesis is impaired with reduced circulating hormone levels after IFN-alpha therapy and the mechanism includes reduction of mRNA expression for various hormones. Induction in vitro of the nuclear enzyme 2'-5-A synthetase in tumour cells correlates with biochemical response and might account for reduced mRNA expression. IFN-alpha induces significantly increased intratumoral fibrosis in carcinoid metastases without significant changes in tumour size. Finally IFN-alpha causes alteration of the major histocompatibility complex (MHC) with increased expression of class I antigens on the tumour cells. The net result of all these effects of IFN-alpha is an antitumour effect in 70-80% of carcinoid tumour patients with biochemical control and abrogated tumour growth for extended periods of time. However, when IFN-alpha therapy is withdrawn tumour progression occurs within 3-9 months, indicating a controlling but not curing effect.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2',5'-Oligoadenylate Synthetase,
http://linkedlifedata.com/resource/pubmed/chemical/Chromogranin A,
http://linkedlifedata.com/resource/pubmed/chemical/Chromogranins,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Substances,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Neuropeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Tachykinins,
http://linkedlifedata.com/resource/pubmed/chemical/neuropeptide K
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1044-579X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:geneSymbol |
neu
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
35-41
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:1353693-2',5'-Oligoadenylate Synthetase,
pubmed-meshheading:1353693-Carcinoid Tumor,
pubmed-meshheading:1353693-Cell Division,
pubmed-meshheading:1353693-Chromogranin A,
pubmed-meshheading:1353693-Chromogranins,
pubmed-meshheading:1353693-Fibrosis,
pubmed-meshheading:1353693-Gene Expression,
pubmed-meshheading:1353693-Growth Substances,
pubmed-meshheading:1353693-Histocompatibility Antigens Class I,
pubmed-meshheading:1353693-Humans,
pubmed-meshheading:1353693-Interferon-alpha,
pubmed-meshheading:1353693-Major Histocompatibility Complex,
pubmed-meshheading:1353693-Neuropeptides,
pubmed-meshheading:1353693-Proto-Oncogene Proteins,
pubmed-meshheading:1353693-Receptor, erbB-2,
pubmed-meshheading:1353693-Receptors, Cell Surface,
pubmed-meshheading:1353693-Tachykinins
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
The action of interferon alpha on human carcinoid tumours.
|
|
pubmed:affiliation |
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Review
|
